RT Journal Article
SR Electronic
T1 Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.01.20048561
DO 10.1101/2020.04.01.20048561
A1 Gritti, Giuseppe
A1 Raimondi, Federico
A1 Ripamonti, Diego
A1 Riva, Ivano
A1 Landi, Francesco
A1 Alborghetti, Leonardo
A1 Frigeni, Marco
A1 Damiani, Marianna
A1 Micò, Caterina
A1 Fagiuoli, Stefano
A1 Cosentini, Roberto
A1 Lorini, Ferdinando Luca
A1 Fabretti, Fabrizio
A1 Morgan, Jonathan
A1 Owens, Benjamin M.J.
A1 Kanhai, Karan
A1 Cowburn, Jim
A1 Reljanovic, Gordana Tonkovivic
A1 Rizzi, Marco
A1 Marco, Fabiano Di
A1 Rambaldi, Alessandro
YR 2020
UL http://medrxiv.org/content/early/2020/05/22/2020.04.01.20048561.abstract
AB COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SAR-CoV-2), resulting in symptoms, such as fever, cough, and shortness of breath. The SARS-CoV-2 virus has also been suggested to initiate a cytokine storm in patients with COVID-19 evidenced by elevated cytokines, such as interleukin-6 (IL-6) and C-reactive protein (CRP).We report preliminary data from 21 patients with COVID-19 who developed pneumonia/acute respiratory distress syndrome (ARDS) and participated in a compassionate-use program at Papa Giovanni XXIII hospital in Bergamo, Italy.All 21 patients received intravenous siltuximab – a chimeric mAb that binds to and blocks the effect of IL-6 – at a dose ranging between 700 to 1,200 mg (median 900 mg). The median age of patients treated was 64 years, and all patients were followed for a median of eight days. Serum CRP levels reduced in all 16 patients with available data following treatment. An improvement in the clinical condition was observed in 33% (7/21) of patients, 43% (9/21) of patients stabilized as evidenced by no clinically relevant change in their condition, and 24% (5/21) experienced a worsening in their condition. Of those patients who experienced a worsening in their condition, one patient died, and one patient experienced a cerebrovascular event.This analysis is presented to inform the medical community of the potential role of siltuximab in treating patients with ARDS secondary to SARS-CoV-2 infection, and a cohort study with patients treated with standard therapy in our hospital is ongoing, and will report the 30-day mortality rates upon completion.Competing Interest StatementJonathan Morgan, Benjamin M.J. Owens, Karan Kanhai and Jim Cowburn are employees of EUSA Pharma. Giuseppe Gritti, Federico Raimondi, Diego Ripamonti, Ivano Riva, Francesco Landi, Leonardo Alborghetti, Marco Frigeni, Marianna Damiani, Caterina Micò, Stefano Fagiuoli, Roberto Cosentini, Ferdinando Luca Lorini, Fabrizio Fabretti, Gordana Tonkovivic Reljanovic, Marco Rizzi, Fabiano Di Marco and Alessandro Rambaldi have no competing interests.Clinical TrialNCT04322188Funding StatementEUSA Pharma funded data collection and processing, supported by Ergomed, and manuscript development, supported by TVF Communications.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made available upon reasonable requests submitted to the authors.